Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 8/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25180088 | 0.83 | HSPB1 (0.56) | HSPB1MAPTNPSR1MEN1PABPC1 | |
| SCHEMBL17571121 | 0.83 | HSPB1 (0.59) | HSPB1MAPTNPSR1MEN1PABPC1 | |
| SCHEMBL20818065 | 0.81 | MEN1 (0.51) | HSPB1MAPTNPSR1MEN1KMT2A | |
| SCHEMBL1978695 | 0.81 | KEAP1 (0.59) | HSPB1MAPTNPSR1MEN1PABPC1 | |
| SCHEMBL25200788 | 0.80 | HSPB1 (0.59) | HSPB1MAPTMEN1PABPC1KMT2A | |
| SCHEMBL1980920 | 0.80 | HSPB1 (0.55) | HSPB1MAPTNPSR1MEN1PABPC1 | |
| SCHEMBL27449389 | 0.78 | HSPB1 (0.70) | HSPB1MAPTNPSR1MEN1PABPC1 | |
| SCHEMBL1980276 | 0.78 | HSPB1 (0.56) | HSPB1MAPTNPSR1MEN1PABPC1 | |
| SCHEMBL16792542 | 0.77 | HSPB1 (0.75) | HSPB1MAPTNPSR1MEN1PABPC1 | |
| SCHEMBL25184221 | 0.77 | KMT2A (0.60) | HSPB1MAPTNPSR1MEN1PABPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6743818-B2 | TREATING ANXIETY, PANIC ATTACKS, OBSESSIVE-COMPULSIVE DISORDERS, PHOBIAS, IMPULSIVE DISORDERS, DRUG ABUSE, COGNITIVE DISORDERS, PSYCHOSES, DEPRESSION AND MOOD DISORDERS | LES LABORATOIRES SERVIER (FR) | 2004-06-01 | — | — | US | disclosed |
| US-20030032812-A1 | Cyclobutaindolecarboxamide compounds | PEGLION JEAN-LOUIS (FR) | 2003-02-13 | — | — | US | disclosed |
| EP-0912554-B1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2002-11-27 | — | — | EP | disclosed |
| US-6452015-B2 | FOR TREATMENT OF ANXIETY, PANIC ATTACKS, OBSESSIVE-COMPULSIVE DISORDERS, PHOBIAS, IMPULSIVE DISORDERS, DRUG ABUSE, COGNITIVE DISORDERS, PSYCHOSES, DEPRESSION AND MOOD DISORDERS | LES LABORATOIRES SERVIER (FR) | 2002-09-17 | — | — | US | disclosed |
| US-6369060-B1 | CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS ANXIETY; 5-METHYL-6-TRIFLUOROMETHYL-1-(6-(2-METHYLPYRIDIN-3-YLOXY)-PYRIDIN-3-YL CARBAMOYL)INDOLINE AND 5-METHYL-1-(6-(2-METHYLPYRIDIN-3-YLOXY) -PYRIDAZIN-3-YLCARBAMOYL)-6-TRIFLUOROMETHYLINDOLINE | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-04-09 | — | — | US | disclosed |
| US-20010044426-A1 | Cyclobutaindolecarboxamide compounds | LES LABORATOIRES SERVIER (FR) | 2001-11-22 | — | — | US | disclosed |
| EP-0912554-A1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997048699-A1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044426-A1 | Cyclobutaindolecarboxamide compounds | HRH4, HTR4, CNR1 | HSPB1 2339/4885MAPT 1453/4885NPSR1 1628/4885 |
| US-20030032812-A1 | Cyclobutaindolecarboxamide compounds | CYP2W1, HRH4, CNR1 | HSPB1 1688/4885MAPT 1006/4885NPSR1 1450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.